$3.69
1.93%
Nasdaq, Nov 14, 10:18 pm CET

AbCellera Biologics Inc Stock price

$3.69
-1.93 34.34% 1M
+1.64 80.00% 6M
+0.76 25.94% YTD
+0.93 33.70% 1Y
-10.58 74.14% 3Y
-16.31 81.55% 5Y
-16.31 81.55% 10Y
-16.31 81.55% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.07 1.93%

New AI Insights on AbCellera Biologics Inc Insights AI Insights on AbCellera Biologics Inc

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$608.9m
Net debt
positive
Cash
$495.7m
Shares outstanding
299.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
31.3 | 32.7
EV/Sales
17.2 | 18.1
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
77.6%
Return on Equity
-15.4%
ROCE
-20.3%
ROIC
-27.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$35.3m | $33.7m
EBITDA
$-232.7m | $-241.7m
EBIT
$-261.3m | $-251.6m
Net Income
$-171.7m | $-186.0m
Free Cash Flow
$-153.1m
Growth (TTM | estimate)
Revenue
7.2% | 17.0%
EBITDA
-4.7% | -7.9%
EBIT
15.2% | 20.1%
Net Income
2.3% | -14.2%
Free Cash Flow
22.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-658.7% | -716.5%
EBIT
-739.7%
Net
-486.0% | -551.5%
Free Cash Flow
-433.5%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
23.9%
Employees
596
Rev per Employee
$50.0k
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a AbCellera Biologics Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
86%
Hold
14%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
35 35
7% 7%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 85 85
0% 0%
241%
- Research and Development Expense 183 183
8% 8%
518%
-233 -233
5% 5%
-659%
- Depreciation and Amortization 29 29
67% 67%
81%
EBIT (Operating Income) EBIT -261 -261
15% 15%
-740%
Net Profit -172 -172
2% 2%
-486%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Neutral
Business Wire
7 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.
Neutral
Seeking Alpha
9 days ago
AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sac...
Neutral
Business Wire
11 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 596
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today